chrisvoncsefalvay/vaers-outcomes huggingface dataset:
16-year old patient who received one dose of the Moderna Covid-19 vaccine; This spontaneous case was reported by a nurse and describes the occurrence of PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (16-year old patient who received one dose of the Moderna Covid-19 vaccine) in a 16-year-old patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 016C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 25-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 25-May-2021, the patient experienced PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (16-year old patient who received one dose of the Moderna Covid-19 vaccine). At the time of the report, PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (16-year old patient who received one dose of the Moderna Covid-19 vaccine) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medications were reported by the reporter.
This spontaneous report has been received from a nurse, concerning a 24 year old female patient. The patient's medical history and concomitant medication were not provided. Concurrent conditions included significant mental disabilities. On 04-JAN-2018, the patient was vaccinated with PNEUMOVAX 23 left deltoid, lot # N020688 and expiration date 09-MAR-2019 for prophylaxis (dose, frequency and route were not provided). On 04-JAN-2018, the patient experienced a reaction that was significantly large on left deltoid area where the patient received the vaccine of PNEUMOVAX 23, the reporter stated that the reaction was red, hard and warm. Furthermore, the patient had trouble putting her coat on an off. The patient sought medical attention and received an unspecified treatment for the adverse events. The outcome of reaction red, hard, warm and movement disorder was unknown. The causal relationship between the adverse events and PNEUMOVAX 23 was not assessed.
Patient received dose 1 moderna 12/29/20, and dose 2 moderna 1/25/21.  Admitted to hospital for fall, altered mental status, hyperglycemia on 2/4/21.
Severe anaphylactic shock Hives, Rash, etc.. Started 3/29/2021 lasting until  4/15/2021 Still feeling off
First symptom was pain in my arm. Then I spiked a low grade fever. Then I got nauseous. Around 7pm I vomited and at 3:30 am I aggressively dry heaved. Throughout the whole time my arm was in pretty serious pain and still is. I woke up this morning and my fever got worse. Nausea still but so far no vomiting.
Swelling of 2nd and 3rd digits of both feet. There was reddish bluish discoloration of the toes. This was sudden in onset without any trauma. Pulses were intact in both feet. Due to the swelling there was tenderness on the balls of the toes and it was painful to touch.  Motrin 200 mg as needed helped relieve it for 1-2 days and then it would recur.  The symptoms were present for 6 weeks and thereafter resolved.
severe back pain; diarrhea; fever; chills; This spontaneous case was reported by a consumer and describes the occurrence of BACK PAIN (severe back pain), DIARRHOEA (diarrhea), PYREXIA (fever) and CHILLS (chills) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced BACK PAIN (severe back pain), DIARRHOEA (diarrhea), PYREXIA (fever) and CHILLS (chills). At the time of the report, BACK PAIN (severe back pain), DIARRHOEA (diarrhea), PYREXIA (fever) and CHILLS (chills) had resolved.            The reporter stated that the patient developed fever, chills, diarrhea, severe back pain and nausea.No concomitant medications were reported.No treatment information was provided.Action taken with mRNA-1273 in response to the events was not applicable.   Most recent FOLLOW-UP information incorporated above includes: On 10-May-2021: Follow-up information received on 10 May 2021.Updated outcome of events.
Redness, Swelling, began the evening of the day that the COVID vaccination was administered. Still today, October 19, mild redness is still noted to the left upper arm.
Serve Chills and body aches and pains. Lasting 24 hours. I took tylenol with minimal effect. Complete recovery after 48 hours after shot
Began having sneezing, runny nose and severe nasal congestion on 7/30. I believe it was allergy related as I was vaccinated and around cats (which I am very allergic to). on 8/2 I went to MD to get a rapid COVID test in order to go in to work (I am a healthcare worker) and was told the test was positive.  I isolated until 8/10 and returned to work on site once cleared. However, a mild cough started 8/10 and has been persistent - unclear if this is related to allergies or aftereffects of COVID.
No further AE information provided.; administration of improperly stored vaccines; This spontaneous report was received from a medical assistant, referring to a 10-year-old patient of unknown gender. The patient's pertinent medical history, concurrent conditions, previous drug reactions, allergies, or concomitant medications were not reported.  On 31-AUG-2020, the patient was vaccinated with an improperly stored varicella virus vaccine live (Oka/Merck) (VARIVAX) injection (lot number T002848 which has been verified to be valid, expiration date reported and validated as 23-JAN-2022) (dosage and frequency were unknown by the reporter; vaccination scheme, route of administration and anatomical site of injection were not reported), as prophylaxis. The administered dose of the vaccine was stored at a temperature of 6 degrees Fahrenheit (F) to 14 F (10.56 F), during a time frame of 50 minutes, as recorded by a digital data logger. There was a previous temperature excursion of 6 F to 14 F (8.47 F), during a time frame of 30 minutes. No further adverse event information was provided.   This is one of several reports received from the same reporter.; Sender's Comments:  US-009507513-2009USA000747: US-009507513-2009USA000777: US-009507513-2009USA000699: US-009507513-2009USA000710: US-009507513-2009USA000736: US-009507513-2009USA000749: US-009507513-2009USA000757: US-009507513-2009USA000762:
Initial report received from a healthcare professional on 08 December 2008. An adult female patient (age not reported) received a first intramuscular deltoid injection of ADACEL (lot number C3027BA) on 23 September 2008 and the following day, she developed a local reaction described as swelling, fever and sore arm. No diagnostic tests or lab data were performed. The patient received treatment symptomatically. The patient recovered. No additional details were reported. Follow-up information received 09 February 2009 from a health care professional. According to the reporter, ADACEL had been administered in the patient's right deltoid and the injection site swelling had been approximately one inch. The patient had no illness at the time of vaccination and the events resolved in five days. This patient's case was created as the result of follow-up received for a cluster of six patients. The other five patients were also identified and are recorded in cases 2008-02996, 2008-03924, 2008-03925, 2008-03926 and 2008-03927, all from the same reporter. Documents held by sender: None.
Information has been received from a lawyer regarding a case in litigation concerning a patient of unknown age and gender. No information was received regarding the patient's past medical history, concurrent conditions, or concomitant medication. The patient's healthcare provider recommended and/or prescribed the ZOSTAVAX to the patient for its intended purpose of permanent prevention and protection against shingles and zoster-related conditions. On or about 02-FEB-2014, a pharmacist at a pharmacy administered the ZOSTAVAX to the patient (lot number, dosage and route of administration not provided). On or about 22-DEC-2016, the patient was treated by a physician for shingles. The patient was diagnosed with shingles and/or other zoster-related injuries after and despite being inoculated with the ZOSTAVAX vaccine, and suffered serious physical, emotional, and economic damages as a result of the patient's injuries. As a direct and proximate result of the ZOSTAVAX vaccine, the patient has and will continue to suffer ongoing injuries, including but not limited to: mental and physical pain and suffering; extensive medical care and treatment for these injuries; significant medical and related expenses as a result of these injuries, including but not limited to medical losses and costs including care for hospitalization (dates unknown), physician care, monitoring, treatment, medications, and supplies; diminished capacity for the enjoyment of life; a diminished quality of life; increased risk of premature death, aggravation of preexisting conditions and activation of latent conditions (unspecified); lost wages; loss of earnings capacity; and other losses and damages. The outcome of the events is considered to be not recovered. Additional information has been requested.
Diurnal Enuresis. Healthy child potty trained with no accidents for two years started having multiple daytime accidents daily the day after MMR Booster was given. No urinary tract infection / bacteria found in urine culture test.
Pt received TDAP 8/4/09 @ 3:50 PM.  On 8/6/09 flu like symptoms (dizzy, fever 101).  Symptoms cleared same day.  Similar reaction in past (per mom) to TD.
Fever, headache which lasted about 24 hours. Extreme tiredness which lasted 48 hours. Advil taken.
Localized swelling at vaccine site with superimposed 1cm blister tx with Bactroban.
On 2/3/99, the vaccinee received her 2nd injection of Engerix-B. On 2/18/99, the vaccinee received her 3rd injection of Engerix-B, 2 weeks after the 2nd injection rather that the recommended interval of 6 months. On an unspecified date, the vaccinee's hair "fell out in clumps". The hair grew back after an unspecified period of time.
Rash at injection site; This case was reported by a pharmacist via call center representative and described the occurrence of injection site rash in a 84-year-old female patient who received Herpes zoster (Shingrix) (batch number P2275, expiry date 25th September 2021) for prophylaxis.   On 3rd July 2019, the patient received the 1st dose of Shingrix (intramuscular). On 5th July 2019, 2 days after receiving Shingrix, the patient experienced injection site rash. On an unknown date, the outcome of the injection site rash was recovered/resolved.   It was unknown if the reporter considered the injection site rash to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported, but it could be 83 or 84 years. The pharmacist stated that the patient received Shingrix and developed a rash at the injection site, about 2 inches in diameter. There was no itching, it was not hot to touch, it was just a rash. The rash has resolved, but the date of resolution was unknown to the pharmacist. The reporter did not consent to follow up. The pharmacist stated that the VAERS report was already completed.  No further details were provided, and specialist neglected to clarify whether safety has permission to follow up.
Developed urticaria arms and legs, few lesions. Appeared as early erythema multiforme.
I had no problem with this vaccination a littl sore but I got it.; This is a spontaneous report from a contactable consumer, the patient. A 57-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: FC3184) via an unspecified route of administration in the right arm on 09Sep2021 at 11:00 (at the age of 57-years-old) as a single dose for COVID-19 immunisation.The patient's medical history and known allergies were reported as none. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient did not receive any medications within two weeks of vaccination. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0177) via an unspecified route of administration in the right arm on 18Aug2021 (at the age of 57-years-old) as a single dose for COVID-19 immunisation. On an unknown date(also reported as 08Aug2021), the patient was a little sore, but he got it and reported that he had no problem with this vaccination. Therapeutic measures were not taken as a result of the reported event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event little sore was unknown at the time of this report.
Swelling left leg with increased temperature; still present at 1 week, post vax. Non-tender now with slight discoloration but not hematoma.
Urticaria at injection site; Injection site itchy; Injection site rash; Injection site redness; This spontaneous case was reported by a nurse (subsequently medically confirmed) and describes the occurrence of INJECTION SITE URTICARIA (Urticaria at injection site), INJECTION SITE PRURITUS (Injection site itchy), INJECTION SITE RASH (Injection site rash) and INJECTION SITE ERYTHEMA (Injection site redness) in a 41-year-old patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 037K20A) for COVID-19 vaccination.     The patient's past medical history included No adverse event (No reported medical history).    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced INJECTION SITE URTICARIA (Urticaria at injection site), INJECTION SITE PRURITUS (Injection site itchy), INJECTION SITE RASH (Injection site rash) and INJECTION SITE ERYTHEMA (Injection site redness). The patient was treated with DIPHENHYDRAMINE HYDROCHLORIDE (ANTIHISTAMINE ALLERGY RELIEF) for Rash, Itchy and Urticaria, at an unspecified dose and frequency. At the time of the report, INJECTION SITE URTICARIA (Urticaria at injection site), INJECTION SITE PRURITUS (Injection site itchy), INJECTION SITE RASH (Injection site rash) and INJECTION SITE ERYTHEMA (Injection site redness) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medication provided
Patients arm is hot to touch, red. Complains of muscle cramping and burning sensation. Not at location of injection site.
The vaccine was administered on 11/13/2003 at the advertised Free Flu Shot Clinic. I started getting a headache and felt a sore throat by 11/15. Right now I experience headaches, occasional fevers, dry mouth, sore throat no cough, muscle pain, general weakness.
Fever, body aches, fatigue, headaches, dizziness, Naseaua,  swollen hard injection site on arm
Systemic: Allergic: Itch Generalized-Severe, Systemic: Allergic: Rash (specify: facial area, extremeties)-Severe, Systemic: skin is hot to touch around injection site-Severe, Additional Details: mom (NAME) called about daughter (NAME) . Mom cell is (PRIVACY). Pt's ph# (PRIVACY). I advised mom pt. is over 18 years old and may be point of contact. Pt got rash on arm and injection site is hot to touch. Advised mom to follow up with primary care doctor.
This spontaneous report as received from a register nurse refers to a female patient of unknown age. Medical history and concurrent conditions were not provided. In 2007 also reported as approximately "7 years", the patient was vaccinated with the first dose of GARDASIL intramuscular (dose, lot number and expiry date were not reported), then voluntarily decided not to continue the series. Patient later decided to resume the series and received her second dose of GARDASIL on 05-JAN-2015 intramuscular (dose, lot number and expiry date were not reported). No adverse effect reported. Additional information has been requested.
I had a delayed menstrual period, by about a week and a half. I experienced more menstrual cramping than normal. When my cycle did begin, it was spotting only, which is unusual for me. I do have an IUD, so my cycle is fairly predictable.
Myalgias, arthralgias, fever, HA, petechial rash.
Information has been received from a nurse practitioner concerning a female who was vaccinated with Gardasil.  Subsequently the patient experienced numbness in her arm and axilla.  No patient could be identified, and at the time the numbness was not associated with the Gardasil vaccination.  Subsequently she recovered without treatment after a few days.  Additional information has been requested.
Pt reported extreme fatigue for 2-3 days, pain and redness at injection site, and joint pain (especially in hips).
Severe pain to the right upper buttocks and hamstring; Bilateral ankle swelling; Shortness of breath; Right leg colour change; Right leg weak from muscle atrophy; Pain with sitting and climbing stairs; Tendinopathy; Hamstring pain severe; This spontaneous case was reported by a nurse and describes the occurrence of MUSCULOSKELETAL PAIN (Severe pain to the right upper buttocks and hamstring), JOINT SWELLING (Bilateral ankle swelling), DYSPNOEA (Shortness of breath), SKIN DISCOLOURATION (Right leg colour change) and MUSCLE ATROPHY (Right leg weak from muscle atrophy) in a 59-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 036A21A and 010M20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Hives, Migraine since 01-Jan-2005, Osteoporosis since 01-Jan-2000 and Anaphylaxis. Concomitant products included VITAMINS NOS (MVI [VITAMINS NOS]) for Supplementation therapy, LORATADINE (CLARITINE) from 02-Mar-2021 to an unknown date and RANITIDINE HYDROCHLORIDE (ZANTAC) for an unknown indication.   On 03-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 03-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient experienced MUSCULOSKELETAL PAIN (Severe pain to the right upper buttocks and hamstring), JOINT SWELLING (Bilateral ankle swelling), DYSPNOEA (Shortness of breath), SKIN DISCOLOURATION (Right leg colour change), MUSCLE ATROPHY (Right leg weak from muscle atrophy), PAIN (Pain with sitting and climbing stairs), TENDON DISORDER (Tendinopathy) and MYALGIA (Hamstring pain severe). The patient was treated with GABAPENTIN ongoing since an unknown date for Adverse event, at a dose of 100 milligram once a day and PARACETAMOL (TYLENOL) ongoing since an unknown date for Adverse event, at a dose of UNK UNK, qd. At the time of the report, MUSCULOSKELETAL PAIN (Severe pain to the right upper buttocks and hamstring), JOINT SWELLING (Bilateral ankle swelling), SKIN DISCOLOURATION (Right leg colour change), MUSCLE ATROPHY (Right leg weak from muscle atrophy), TENDON DISORDER (Tendinopathy) and MYALGIA (Hamstring pain severe) outcome was unknown, DYSPNOEA (Shortness of breath) was resolving and PAIN (Pain with sitting and climbing stairs) had not resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Weight: loss (Low) 10 lb weight loss.     For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   On 12-Jan-2012, the patient started NSAIDs treatment for hives.  The patient went to orthopedic urgent care and was treated for tendinopathy. The patient went for physical therapy for two to three times per week in the past three months. The patient was home care nurse and since past seven months was resting at home.   This case was linked to MOD-2021-294480 (Patient Link).
This is a spontaneous report from a contactable nurse (patient herself). A 28-year-old female patient received second dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number: EK4176, expiry date not reported), via an unspecified route of administration in the left deltoid on 09Jan2021 at single dose for COVID-19 immunisation. Medical history included ongoing ulcerative colitis from 2009 and exposure to a positive COVID patient on 08Jan2021. The patient also had a sinus drainage down the back of her throat. It went away but started back up on 09Jan2021. It is the same since last night but had improved from over the weekend. Concomitant medications were not reported. The patient previously took first dose of bnt162b2 (lot number: EH9899, expiry date not reported) on 21Dec2020 at single dose for COVID-19 immunisation. The patient had her second COVID19 Vaccine dose last Saturday and reported having a "weird reaction". She had already gone to urgent care and was told to call. She experienced rash from Monday evening in the knees and elbows which spread to face and joint areas (knees, ankles, toe, hip, wrist), which occurred as splotches of red; some were raised bumps with symptoms relieved with Benadryl. Patient said that she was not sure if she was having a reaction or not to the Pfizer COVID Vaccine. She was just in urgent care that morning and was going to primary care that afternoon. Urgent care thought she was having a reaction. She got her second dose of the vaccine on Saturday morning, 09Jan2021. That night she had the typical immune response.  She had chills, sore muscles, sore throat, fatigue, and facial pain from sinus pressure, which lasted through Sunday. She took Sudafed PE and Monday when she woke up, she felt normal. She experienced rash from Monday evening in the knees and elbows which spread to face and joint areas (knees, ankles, toe, hip, wrist, fingers, feet, face, upper arms), rash which occurred as splotches of red; some were raised bumps with symptoms relieved with Benadryl. Benadryl helped it get better, but after it wears off the rash comes back and it gets worse. It had spread to different areas. Sometimes, it will be really bad on her knees, then other times really bad on her elbows or hips. Her hips were bad last night. Now it is on the bottom of her feet and on her knees again. She asked if these were something that have been previously reported. All of these symptoms, besides the rash, she felt like she had the flu. It knocked her on her ass it was pretty terrible. But it went away and she felt better. It was a typical immune response so she would say it was not serious. The patient underwent lab tests and procedures which included sars-cov-2 test: negative on 13Jan2021. Clinical outcome of events chills, sore muscles, sore throat, fatigue, and facial pain from sinus pressure was recovered on 11Jan2021, while for the other events was not recovered.